Two other PI3K inhibitors have also recently been approved: duvelisib (PI3Kγ/δ) for relapsed CLL or SLL [51,52] and copanlisib (pan-PI3K) for relapsed FL [53,54,55,56]. This evidence concerns the gene PIK3CA and B-cell chronic lymphocytic leukemia.